Molecular classification of the portec-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy

HIGHLIGHTS

• who: Alicia León-Castillo et al. from the Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands , Department of Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands , Department of Clinical Oncology, Barts Health National Health Service Trust, London, United Kingdom , Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia , Division of Medical Oncology and Hematology, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada , Department of Medical Oncology, Gustave Roussy, Villejuif, France , Department of Gynecology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands , Department of Pathology, Barts Health National Health Service Trust . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.